Shopping Cart
- Remove All
- Your shopping cart is currently empty
T025 is a pan CLK inhibitor with Kds of 4.8, 0.096, 6.5, 0.61, and 0.074 nM for CLK1-4, respectively. T025 displays anti-proliferative activities with IC50s of 30-300 nM in hematological and solid cancer cell lines. T025 can be used in studies about MYC-driven diseases.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $146 | In Stock | |
5 mg | $372 | In Stock | |
10 mg | $556 | In Stock | |
25 mg | $896 | In Stock | |
50 mg | $1,220 | In Stock | |
100 mg | $1,650 | In Stock | |
500 mg | $3,290 | In Stock | |
1 mL x 10 mM (in DMSO) | $397 | In Stock |
Description | T025 is a pan CLK inhibitor with Kds of 4.8, 0.096, 6.5, 0.61, and 0.074 nM for CLK1-4, respectively. T025 displays anti-proliferative activities with IC50s of 30-300 nM in hematological and solid cancer cell lines. T025 can be used in studies about MYC-driven diseases. |
Targets&IC50 | CLK2:0.096 nM (kd), CLK1:4.8 nM (kd), CLK3:6.5 nM (kd), CLK4:0.61 nM (kd) |
In vitro | In MDA-MB-468 cells, T025 (1-1000 nM) dose-dependently suppresses cell growth and reduces pCLK2 and CLK2 phosphorylation levels[1]. |
In vivo | In Balb/c nude mice, gavage administration of T025 (50 mg/kg) suppresses tumor growth and < 10% nadir body weight loss. Gavage administration of T025 (50 mg/kg) inhibits the CLK-dependent phosphorylation and decreases the RPS6KB1 exon 7 and BCLAF1 exon 11 percentage splice-in values[1]. |
Molecular Weight | 382.42 |
Formula | C21H18N8 |
Cas No. | 2407433-00-3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
Solubility Information | DMSO: 10 mg/mL (26.15 mM), Sonication is recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.